Fracture Pattern Following Bilateral Sagittal Split Osteotomy With or Without Impacted Third Molars
Launched by KIMIE BOLS ØSTERGAARD · Mar 24, 2024
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how the timing of wisdom tooth removal affects the results of jaw surgery for patients with severe dental and facial issues. Specifically, it aims to find out whether removing wisdom teeth before surgery (pre-operative) or during the surgery (inter-operative) makes a difference in complications and how patients feel about their experience. Participants will be divided into two groups: one group will have their wisdom teeth taken out six months before the jaw surgery, while the other group will have them removed at the same time as the surgery.
To be eligible for this trial, participants should be between 18 and 75 years old and scheduled for surgery to correct facial deformities that involve certain types of jaw surgery. Those with certain conditions, like well-functioning wisdom teeth or previous jaw fractures, will not be included. If you join this trial, you can expect to undergo either of the two approaches for wisdom tooth removal, and your recovery and experiences will be monitored closely to help answer the trial's questions. This research aims to improve future treatment options for patients facing similar dental and facial challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients scheduled for surgical correction of facial deformities involving BSSO or bimaxillary surgery with bilateral asymptomatic impacted mandibular third molars
- • Age between 18 and 75 years
- Exclusion Criteria:
- • Fully erupted and well-functioning mandibular third molar
- • Unilateral impacted mandibular third molar
- • Pathology associated with the impacted mandibular third molar
- • BSSO combined with genioplasty
- • Previous mandibular fractures
- • Present neurosensory disturbances of the inferior alveolar nerve
- • Systemic bone disease or arthritis
- • Physical status classification system, ASA Class III or IV, specified patients with severe systemic disease ore patients with severe systemic disease that is constant threat to life
- • Failure to attend the entire observation period
About Kimie Bols østergaard
Kimie Bols Østergaard is a dedicated clinical trial sponsor with a focus on advancing medical research and improving patient outcomes. With a commitment to scientific integrity and ethical practices, Kimie leads initiatives that bridge innovative therapeutic developments with rigorous trial methodologies. The organization prioritizes collaboration with healthcare professionals and stakeholders, ensuring comprehensive oversight and adherence to regulatory standards. Through its strategic approach, Kimie Bols Østergaard aims to contribute significantly to the field of clinical research, driving forward the discovery of impactful treatments and enhancing the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aalborg, , Denmark
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported